MedTrace Logo

Insulin in Total Parenteral Nutrition

NCT02706119 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2018-05-24

No results posted yet for this study

Summary

Analyze the level of metabolic control achieved with a routine of regular insulin in the parenteral nutrition (PN) reservoir in addition to subcutaneous glargine insulin, versus only regular insulin in the PN reservoir.

Conditions

Interventions

DRUG

Subcutaneous glargine insulin

Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.

DRUG

Regular insulin added to TPN bag

Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.

Sponsors & Collaborators

  • Fundación Pública Andaluza Progreso y Salud

    lead OTHER

Principal Investigators

  • Gabriel Olveira Fuster, PhD · Hospital Regional de Malaga

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2018-03-31
Completion
2018-04-04

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02706119 on ClinicalTrials.gov